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Introduction: TNF Receptor-Associated Factor 5 (TRAF5) has been shown to be associated with autoimmune disease.
The current study sought to investigate the potential association of TRAF5 with acute anterior uveitis (AAU) and
pediatric uveitis in Han Chinese.
Methods: Three TRAF5 SNPs were analyzed in 450 AAU patients with or without ankylosing spondylitis (AS), 458
pediatric uveitis patients, and 1,601 healthy controls by using polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) or TaqMan SNP Genotyping Assay. Numerous variables were evaluated, including age, sex
distribution, and clinical and laboratory observations.
Results: Two SNPs (rs6540679, rs12569232) of TRAF5 were associated with pediatric uveitis, and rs12569232 also
showed a relation with the presence of microvascular leakage. No significant associations were found when patients
were subdivided according to their rheumatoid factor (RF) or anti-nuclear antibody (ANA) status or whether they had
juvenile idiopathic arthritis (JIA). Rs12569232 predisposed to AAU and its subgroups (with ankylosing spondylitis (AS) or
HLA-B27 positive). No association was found between rs10863888 and either pediatric uveitis or AAU.
Conclusion: This study revealed that TRAF5 is involved in the development of AAU and pediatric uveitis. Further
stratified analysis according to the clinical and laboratory observations suggested that rs12569232/TRAF5 may play a
role in the development of retinal vasculitis.Introduction
Uveitis is a manifestation of complex processes and a major
etiologic factor of visual loss. Uveitis can be categorized
into several phenotypes. Among them, acute anterior
uveitis (AAU) is the most common entity encountered
[1]. Many patients with AAU are HLA-B27 positive, and
a strong association with ankylosing spondylitis (AS) is
observed in this subgroup of patients [2,3]. Similarly,
30% to 50% of patients with HLA-B27-positive AS will
have an episode of AAU in the course of their disease
[4-6]. Both heredity and environmental factors, especially
bacterial triggers, are thought to be involved in the* Correspondence: peizengycmu@126.com
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reproduction in any medium, provided the ordevelopment of AAU and AS [7-9]. Half of the AAU cases
are HLA-B27 positive [8], and the association of HLA-B27
with AS is found in almost all ethnic groups [10-13].
Pediatric uveitis is one of the most common reasons
for childhood blindness. Children with uveitis comprise
2.2% to 10.6% of the total number of uveitis patients
[14,15], and anterior uveitis is the most frequent type of
involvement in the majority of cases [16,17]. About 60% of
pediatric uveitis cases are diagnosed as idiopathic uveitis,
followed by juvenile idiopathic arthritis (JIA)-associated
anterior uveitis [17]. Rheumatoid factor (RF), anti-nuclear
antibody (ANA), and fundus fluorescein angiography
(FFA) are regarded as important tests for pediatric uveitis
and JIA.
Recent years witnessed a rapid improvement in the
understanding of the genetic basis of AS, AAU and
pediatric uveitis, including more than 69 subtypes of
HLA-B27, as well as other immune-response genes, suchtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical features of the investigated AAU patients
Clinical features n (total = 450) %




AAU patients with AS 209 46.4
AAU patients without AS 241 53.6
HLA-B27(+) 267 (332 tested) 80.4
HLA-B27(−) 65 (332 tested) 19.6
AAU, acute anterior uveitis; AS, ankylosing spondylitis. +, having this feature;
-, not having this feature.
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AAU [19,20], and chemokine and chemokine-receptor
genes in pediatric uveitis [21]. The involvement of these
latter genes is, however, not consistent among the various
ethnic groups throughout the world, as evidenced by
association studies concerning IL-23R in AS [22-24],
and further studies in well-defined ethnic populations
are needed to understand how non-HLA-B27 genes
can contribute to the development of autoimmune or
autoinflammatory diseases.
TNF receptor-associated factor 5 (TRAF5) is a signal
transducer that links members of the tumor necrosis factor
(TNF)-receptor family to different signaling pathways,
regulating NF-κB and probably JNK activation [25-27].
NF-κB is considered a common transcription factor that is
critical for innate and adaptive immunity and has been im-
plied to play a role in autoimmune and autoinflammatory
diseases, such as JIA [28], rheumatoid arthritis [29],
and AS [30]. Inhibition of NF-κB has been verified as a
treatment for AAU, experimental autoimmune encephalo-
myelitis, experimental autoimmune uveitis and inflamma-
tory arthritis [31-34]. Recent studies have shown that
TRAF5 polymorphisms are associated with rheumatoid
arthritis (RA) [35]. As mentioned earlier, uveitis and
arthritis have overlapping manifestations, and because
the relation between TRAF5 with uveitis has not yet
been reported, we decided to investigate the role of




The study included 450 AAU patients, 458 pediatric
uveitis patients, and 1,601 healthy adult controls. All
patients and controls were Han Chinese, as confirmed
by their ID cards. The diagnosis of AS was based on the
modified New York criteria [36], and AAU patients were
diagnosed principally according to clinical manifestations
[37,38]. Pediatric uveitis was defined as uveitis first seen in
patients younger than 16 years. Children with Behḉet
disease, Vogt-Koyanagi-Harada syndrome, or definite in-
fectious uveitis entities were excluded from the study. JIA
was defined as arthritis of at least 6 weeks’ duration
without any other identifiable cause in children younger
than 16 years. Subjects were excluded if they had Behḉet
disease, Vogt-Koyanagi-Harada syndrome, or another type
of uveitis. Blood samples of the patients and controls were
obtained from the Uveitis Study Center of the Sun Yat-sen
University (Guangzhou, P.R. China) and the First Affiliated
Hospital of Chongqing Medical University (Chongqing,
P.R. China) between 2005 and 2013. All the subjects
participating in our study came from all over the country,
as evidenced by their ID cards. The study was approved by
the Local Ethics Research Committee of The First AffiliatedHospital of Chongqing Medical University, Chongqing,
China (Permit Number: 2009–201008), and all tested
subjects gave their written informed consent; for children,
the informed consent was obtained from their parents
or guardians. The procedures followed the tenets of the
Declaration of Helsinki.
Clinical and laboratory observations
Pediatric uveitis patients underwent a uveitis screening
protocol encompassing ANA (n = 176; positive rate was
17.0%), RF (n = 187; positive rate was 15.5%), and FFA
(n = 271; microvascular leakage rate detected by FFA
was found in 63.5% of tested patients). An ANA titer above
1:100 and an RF level above 20.0 IU/ml were considered
positive. FFA was considered a positive result when dye
leakage from a retinal vessel was observed. Of the AAU
patients, 209 had AS, and of the 332 subjects tested for
HLA-B27, 267 (80.4%) were positive. All these tests were
performed in the First Affiliated Hospital of Chongqing
Medical University (Chongqing, P.R. China). The clinical
characteristics of the patients are shown in Tables 1 and 2.
SNP selection, DNA extraction, and genotyping
The polymorphisms used in this study were based on earl-
ier reports in RA [35], including rs6540679, rs7514863,
rs12569232, and rs10863888. Genomic DNA samples
of patients and healthy controls were extracted by using
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA,
USA) and genotyped by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
for rs6540679 or by TaqMan SNP Genotyping Assay for
rs12569232 (TaqMan assay ID: C_26176827_20) and
rs10863888 (TaqMan assay ID: C_26176858_10) using the
ABI 7500 Real-Time PCR system. Digestion PCR products
were visualized on a 4% agarose gel and stained with
GoldViewTM (SBS Genetech, Beijing, China). Unfortu-
nately, as we designed six PCR primers for rs7514863,
none of their PCR product was satisfactory to go to the
digestion step. No TaqMan SNP Genotyping Assay for it
Table 2 Clinical features of the investigated pediatric
uveitis patients
Clinical features Pediatric uveitis
n (total = 458) %




Pediatric uveitis with JIA 60 13.1
FFA(+) 172 (271 tested) 63.5
ANA(+) 30 (176 tested) 17.0
RF(+) 29b (187 tested) 15.5
JIA, juvenile idiopathic arthritis; FFA, fundus fluorescein angiography; ANA,
anti-nuclear antigen; RF, rheumatoid factor. +, having this feature; -, not
having this feature.
Table 3 Genotype and allele frequency analysis between









CC 4 NS 20
CG 28 7.43 × 10-10 (0.283) 304
GG 418 7.44 × 10-10 (3.314) 1,277
C 4.0% 2.12 × 10-9 (0.346) 10.7%
G 96.0% 89.3%
rs10863888
AA 50 NS 170
AG 202 NS 650
GG 196 NS 754
A 33.7% NS 31.4%
G 66.3% NS 68.6%
rs6540679
AA 17 NS 81
AG 171 NS 497
GG 260 NS 982
A 22.9% NS 21.1%
G 77.1% NS 78.9%
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found to have been significantly associated with RA.
All the tests were performed according to the manufac-
turers’ instructions. Direct sequencing was also performed
by the Beijing Biomed Co., Ltd (Beijing, China), by using
randomly selected subjects (10% of all samples) to validate
the method used in this study.
Statistical analysis
Test of Hardy-Weinberg equilibrium (HWE), evaluation
of genotype and allele frequencies, and calculation of odds
ratios (ORs) and 95% confidence intervals (95% CIs) were
done by following the method of Chen et al. [39]. The
P values were corrected (Pc) by using the Bonferroni
correction method. Pc < 0.05 was considered significant.
The linkage disequilibriums (LDs) of these tested SNPs
were compared by using Haploview v3.32.
Results
TRAF5 gene implicated in susceptibility to acute
anterior uveitis
The three SNPs (rs6540679, rs12569232, rs10863888) of
TRAF5 were successfully genotyped and conformed to
Hardy-Weinberg expectation in controls. The chosen SNPs
were not in linkage disequilibrium with each other.
The frequencies of the CG genotype and C allele of
rs12569232 in the AAU group were much lower than
those in the healthy controls (Pc = 7.43 × 10
-10; OR, 0.283;
Pc = 2.12 × 10
-9; OR, 0.346 respectively) whereas the fre-
quencies of the GG genotype (Pc = 7.44 × 10
-10, OR 3.314)
and G allele were significantly higher (Table 3). Further
analysis was done in the following four subgroups: AAU
with AS (AAU+AS+), AAU without AS (AAU+AS-), HLA-
B27-positive AAU (AAU+B27+), and HLA-B27-negative
AAU (AAU+B27-). Our data revealed that the associated
polymorphisms of rs12569232/TRAF5 were consistent among
the AAU subgroups investigated (Table 4). We failed tofind a significant association with rs6540679 or rs10863888
in the AAU group and its subgroups (data not shown).TRAF5 gene implicated in susceptibility to pediatric
uveitis
In total, 458 pediatric uveitis patients were genotyped for
three TRAF5 SNPs. The frequencies of the CG genotype
and C allele of rs12569232 were significantly decreased in
cases compared with normal controls (Pc = 3.85 × 10
-6;
OR, 0.420; Pc = 3.0 × 10
-8; OR, 0.390), whereas the GG
genotype (Pc = 2.41 × 10
-7; OR, 2.574) and G allele were
both increased. As to rs6540679, a decreased frequency of
the AA genotype was observed with a Pc = 5.64 × 10
-5;
OR, 0.163. No association was found for rs10863888
(Table 5). We subsequently compared pediatric uveitis
patients with controls on the basis of clinical and laboratory
observations. JIA, FFA, ANA, and RF were chosen as our
target factors. The results revealed that the frequency of
the GG genotype and G allele of rs12569232 was increased
in the patient group with microvascular leakage detected
by FFA, whereas the CG genotype and C-allele frequencies
were decreased compared with healthy controls (Table 6).
No association was found for rs12569232 in patients
that had a negative FFA examination. FFA status was not
associated with rs10863888 and rs6540679. Furthermore,
no significant associations were found when patients were
Table 4 Genotype and allele frequency analysis between rs12569232/TRAF5 polymorphisms in AAU subgroups and
healthy controls
AAU Genotype and allele frequency of rs12569232
Subgroups CC CG GG C
AAU+AS+(n = 209) 3 14 192 4.8%
Pc (OR) NS 1.36 × 10
-4 (0.306) 3.10 × 10-4 (2.866) 5.60 × 10-4(0.417)
AAU+AS-(n = 241) 1 14 226 3.3%
Pc (OR) NS 5.38 × 10
-6 (0.263) 2.0 × 10-6 (3.823) 1.24 × 10-6 (0.285)
AAU+B27+(n = 267) 2 18 247 4.1%
Pc (OR) NS 1.12 × 10
-5 (0.308) 7.85 × 10-6 (3.133) 7.48 × 10-6 (0.357)
AAU+B27-(n = 65) 1 3 61 3.8%
Pc (OR) NS 0.036 (0.206) NS 0.048 (0.332)
As rs6540679 and rs10863888 did not show a significant association, they are not shown in the subgroups table.
+, having this feature; -, not having this feature.
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whether they had JIA (data not shown).
Discussion
In the present study, we aimed to determine whether
TRAF5 gene polymorphisms were associated with AAU
and pediatric uveitis in a Han Chinese population. The
results showed that rs12569232 polymorphisms of the
TRAF5 gene were associated with both AAU and its
subgroups (either accompanied by AS or HLA-B27Table 5 Genotype and allele-frequency analysis of TRAF5









CC 0 0 20
CG 41 3.85 × 10-6 (0.420) 304
GG 416 2.41 × 10-7 (2.574) 1,277
C 4.5% 3.0 × 10-8 (0.390) 10.7%
G 95.5% 89.3%
rs10863888
AA 47 NS 170
AG 220 NS 650
GG 191 NS 754
A 34.3% NS 31.4%
G 65.7% NS 68.6%
rs6540679
AA 4 5.64 × 10-5 (0.163) 81
AG 152 NS 497
GG 295 NS 982
A 17.7% NS 21.1%
G 82.3% NS 78.9%positive). The same polymorphism was also associated
with pediatric uveitis and, most notably, in the group
showing retinal vascular leakage. The frequencies of the
CG genotype and C allele of rs12569232 in these test
groups were much lower than in the healthy control
group, whereas the frequencies of the GG genotype and G
allele were significantly higher. A significant association
with rs6540679 was found in the pediatric uveitis patients,
whereas the frequency of the AA genotype was lower in
the patient group compared with controls. No association
was found with rs10863888 either in AAU and its sub-
groups or in pediatric uveitis and its subgroups. These
data suggest that TRAF5 gene polymorphisms may increase
the risk for AAU and pediatric uveitis. In the latter group,
the association increases the risk for the occurrence of
retinal vasculitis.
To our knowledge, this is the first report addressing
an association between genetic variants of TRAF5 and
uveitis. The similar association of rs12569232 with these
two widely differing uveitis entities described in our study
may be due to the fact that the eye only has a limited
repertoire with which to respond to inflammation and
that TRAF5 is possibly involved in this final common
intraocular inflammatory pathway. Our group is currently
studying the role of TRAF5 in other uveitis entities, such
as Vogt-Koyanagi-Harada syndrome and Behḉet disease,
and data obtained so far confirm the results presented
here. As yet, no other studies have shown an association
of rs12569232 TRAF5 polymorphisms with disease.
TRAF5, a tumor necrosis factor receptor-associated
factor family protein, acts as an activator of the TNF-
induced NF-κB signal pathway [25,40]. It is expressed in
various organs and peripheral blood [25,41,42]. Over-
expression can lead to inflammation and autoimmune
disease, and it has also been shown to protect cells from
apoptosis [26,40,43-46]. In view of the findings mentioned
earlier, we hypothesized that TRAF5 may also mediate the
Table 6 Genotype and allele-frequency analysis of rs12569232/TRAF5 polymorphisms in pediatric uveitis-subgroup
patients accompanied by FFA-positive patients
SNP Subgroup Genotype Pediatric uveitis Controls Pc OR (95% CI)
rs12569232 FFA + (n = 172) GG 157 1,277 0.003 2.65 (1.542-4.573)
CG 15 304 0.012 0.408 (0.237-0.702)
CC 0 20 NS
G 329 2,858 7.68 × 10-3 2.640 (1.555-4.483)
C 15 344 7.68 × 10-3 0.379 (0.223-0.643)
SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NS, no statistical difference. Pc, Bonferroni corrected P value compared with normal
controls. +, having this feature, -, not having this feature.
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was based on previous studies concerning the association
with rheumatoid arthritis (see Potter et al. [35], Supple-
mentary Table) [35] and the observed overlap between
uveitis and arthritis. We chose rs6540679, rs12569232,
and rs10863888 as our target SNPs for TRAF5. We also
wanted to include rs7514863, an upstream SNP of TRAF5
shown to be associated with RA [35], but failed to
develop a reliable PCR method. Moreover, a TaqMan SNP
Genotyping Assay is not yet available for rs7514863.
Our data showed a significant association with poly-
morphisms of rs6540679 and rs12569232 that were not
observed in RA. The reasons for this discrepancy are
unclear, but it could point to different roles of TRAF5 in
the pathogenesis of arthritis as compared with intraocular
inflammation. We furthermore investigated whether these
mutations were related not only to the occurrence of dis-
ease but also to the disease activity. This was done by ana-
lyzing a large number of laboratory parameters for pediatric
uveitis, including ANA, RF, ASO (anti-streptolysin “O”),
CRP (C-reactive protein), ANCA (anti-neutrophil cyto-
plasmic antibodies), and ESR (erythrocyte sedimentation
rate). In AAU, we analyzed the HLA-B27 status of the
patients [47]. Clinical manifestations were analyzed for
pediatric uveitis with JIA (both oligoarthritis and
polyarthritis), arthritis deformans, retinal vasculitis (deter-
mined by FFA test) [17,48], and the presence of AS was
estimated for AAU patients. Positivity rates of the labora-
tory tests were below 15%, and no associations with TRAF5
gene polymorphisms could be found (data not shown). As
mentioned, we did note an association between rs12569232
and the presence of retinal vascular leakage in pediatric
uveitis patients. Why rs12569232 is associated with retinal
vasculitis in PU and why AAU patients with this mutation
do not have retinal vasculitis is an intriguing observation
that deserves further study.
Further study also is needed to correlate the TRAF5
genetic data with ophthalmic findings, such as the response
to the use of steroids, visual outcome, and recurrence rate.
This was not yet possible in the current study, because
many of our patients are referred to us by other centers all
over China, and the exact medical history concerningtreatment and further follow-up of patients is often diffi-
cult. Furthermore subdivision into several groups would
markedly reduce sample size, thereby reducing the statis-
tical power of the analysis. A future prospective multicenter
trial would allow sufficient sample size to address this issue.
We made the following efforts to validate the obtained
data. First, the sample sizes of patients and normal controls
were large enough to ensure an association analysis. We
excluded non-Han patients, and healthy controls were
obtained from the same geographic regions as the patients
to avoid confounding by genetic ancestry. Furthermore,
the diagnosis was performed strictly according to the
criteria described previously. Additionally, 10% of the
total samples were randomly selected to undergo direct
sequencing so as to validate the results of genotyping
with PCR-RFLP and TaqMan SNP Genotyping Assay.
Despite these efforts, some limitations exist in our
study. We compared our pediatric uveitis patients with
a large group of normal healthy adults, instead of using
age-matched controls. The large size of our ethnically
matched control group (n = 1,601) ensures that we
obtained a good representation of the frequency of TRAF5
gene polymorphisms in the Han Chinese population. As
this study was performed only in Han Chinese, further
research should be done in other ethnic populations to
confirm the results. Because our study recruited patients
visiting a department of ophthalmology, only uveitis pa-
tients were included. Whether the same relation exists
between the TRAF5 gene and AS patients without uveitis
remains to be studied. We studied only the relation with
three TRAF5 SNPs, and further studies, including other
SNPs of TRAF5, must be performed. Whether the TRAF5
polymorphisms described here play a functional role is not
yet clear, and further functional and association studies are
needed to address this issue. A recent study by our group
showed that healthy control carriers of the GG genotype
in SNP rs6540679/TRAF5 had a higher TRAF5 mRNA
expression level and enhanced TNF-α and IL-6 secretion
compared with AA and AG carriers (unpublished data). We
were not able to find an effect of the various rs12569232
TRAF5 genotypes on TRAF5 mRNA expression by stimu-
lated peripheral blood mononuclear cells (data not shown),
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an association in linkage disequilibrium with the causative
locus. It should also be noted that the GG phenotype of
rs12569232 is quite common in China and that TRAF5
is only one gene in a multihit process involving a large
number of genes involved in the regulation of an inflam-
matory immune response, finally leading to the expression
of clinical uveitis.
Conclusion
Our study investigated the association of TRAF5 with two
common forms of uveitis (AAU and pediatric uveitis) and
identified rs12569232 polymorphisms were associated with
AAU and its subgroups (accompanied by either AS or
HLA-B27 positive). The same mutation was also found in
pediatric uveitis and significantly in the group showing
retinal vascular leakage, which suggests that rs12569232/
TRAF5 may play a role in the development of retinal
vasculitis.
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